动物药物市场机会、成长动力、产业趋势分析及 2025-2034 年预测

2024 年全球动物药物市场规模达 433 亿美元，预计 2025 年至 2034 年复合年增长率为 6.1%。市场成长的动力包括宠物拥有增加、牲畜医疗保健需求增加以及兽医学的进步。随着越来越多的人将宠物视为伴侣，对用于治疗各种健康问题的高品质药品的需求也在激增。

同样，畜牧业也越来越重视疾病预防和生产力提高，从而刺激了对专用药物的需求。关节炎、糖尿病和心血管疾病等动物慢性疾病的发生率不断上升，导致兽医支出增加，促使人们开发更有效的治疗方案。预防保健意识的不断增强，加上创新兽药的监管批准，进一步加速了市场的成长。随着研发工作的不断开展和兽医护理服务可及性的提高，该行业有望继续扩张。

药品创新与分销网络的改善使得动物药品在各个地区更容易取得。政府和私人组织正在积极支持兽医研究，从而引入旨在最大限度缩短恢復时间和增强动物整体健康的先进治疗方法。此外，宠物保险覆盖率的激增也鼓励宠物主人投资高品质的药物，确保更好地遵守治疗法规。

2024 年，药品领域以 238 亿美元的规模占据市场主导地位，这得益于其在治疗感染、发炎和寄生虫感染方面的重要作用。兽药的配方越来越多地用于提供有针对性的治疗，减少副作用并提高疗效。人畜共通传染病发生率的上升也增加了对先进药物的需求，促使製药公司投资于尖端研究。宠物主人越来越积极关注宠物的健康，选择能够更快恢復并带来长期益处的处方药。人们对抗生素抗药性的日益担忧推动了益生菌和免疫调节剂等替代疗法的采用，进一步使药物模式多样化。

2024 年，伴侣动物占了 59.2% 的市场份额，反映出越来越多的家庭收养宠物并重视宠物的医疗保健。可支配收入的增加，加上对宠物的情感依恋，导致兽医支出增加，特别是在专门药物方面的支出。随着宠物主人寻求延长宠物的寿命并提高其生活质量，对疫苗和营养补充剂等预防性治疗的需求正在激增。兽医诊断技术的进步也在该领域的发展中发挥关键作用，实现了早期疾病检测和个人化治疗方法。

2024 年，北美占据了 41.4% 的市场份额，由于宠物拥有率高和兽医医疗保健体系完善，保持了主导地位。该地区重要的畜牧业继续推动对旨在改善畜群健康和生产力的药品的需求。不断扩大的研究计划，加上对创新兽医治疗日益加强的监管支持，正在促进产业成长。生物製剂和基因疗法等先进治疗方案的日益普及正在塑造动物保健的未来，确保整个地区对药品的持续需求。

目录

第一章：方法论与范围

第二章：执行摘要

第三章：行业洞察

• 产业生态系统分析
• 产业衝击力
  • 成长动力
    • 动物疾病发生率上升
    • 日益关注畜牧业生产力
    • 宠物保险需求激增
    • 政府对动物福利的倡议和支持日益增多
    • 加强研发活动推广兽医学进步
    • 扩大网路兽医药房
  • 产业陷阱与挑战
    • 不良副作用和药品召回
    • 动物药物研发成本高
• 成长潜力分析
• 监管格局
  • 北美洲
  • 欧洲
  • 亚太地区
• 政策格局
• 产品线分析
• 投资者概览
• 差距分析
• 消费者行为趋势
• 波特的分析
• PESTEL分析

第四章：竞争格局

• 介绍
• 公司矩阵分析
• 公司市占率分析
• 主要市场参与者的竞争分析
• 竞争定位矩阵
• 策略仪表板

第五章：市场估计与预测：按产品，2021 年至 2034 年

• 主要趋势
• 药物
  • 抗寄生虫药
  • 消炎剂
  • 抗感染药物
  • 皮质类固醇
  • 镇静剂
  • 心血管药物
  • 胃肠道药物
• 疫苗
  • 减毒活疫苗（MLV）
  • 灭活疫苗
  • 重组疫苗
• 药物饲料添加剂
  • 抗生素
  • 维生素
  • 胺基酸
  • 酵素
  • 抗氧化剂
  • 益生元和益生菌
  • 矿物质
  • 其他药物饲料添加剂

第六章：市场估计与预测：依动物类型，2021 年至 2034 年

• 主要趋势
• 伴侣动物
  • 狗
  • 猫
  • 马匹
  • 其他伴侣动物
• 家畜
  • 家禽
  • 猪
  • 牛
  • 鱼
  • 其他牲畜

第七章：市场估计与预测：依管理路线，2021 年至 2034 年

• 主要趋势
• 口服
• 注射剂
• 外用
• 其他给药途径

第八章：市场估计与预测：按配销通路，2021 年至 2034 年

• 主要趋势
• 兽医院药房
• 电子商务
• 零售药局

第九章：市场估计与预测：按地区，2021 年至 2034 年

• 主要趋势
• 北美洲
  • 我们
  • 加拿大
• 欧洲
  • 德国
  • 英国
  • 法国
  • 西班牙
  • 义大利
  • 波兰
  • 荷兰
• 亚太地区
  • 中国
  • 日本
  • 印度
  • 澳洲
  • 韩国
  • 台湾
• 拉丁美洲
  • 巴西
  • 墨西哥
  • 阿根廷
• 中东和非洲
  • 南非
  • 海湾合作委员会国家
  • 以色列

第十章：公司简介

• Agrolabo
• Boehringer Ingelheim International
• Ceva Santé Animale
• Chanelle Pharma
• Dechra Pharmaceuticals
• Durvet
• Elanco Animal Health
• Endovac Animal Health
• HIPRA
• Indian Immunologicals
• Merck
• Norbrook
• Neogen Corporation
• Symrise
• Vetoquinol
• Virbac
• Zoetis

The Global Animal Drugs Market reached USD 43.3 billion in 2024 and is projected to register a CAGR of 6.1% from 2025 to 2034. The market growth is driven by a combination of rising pet ownership, increasing demand for livestock healthcare, and advancements in veterinary medicine. As more people embrace pets as companions, the need for high-quality pharmaceuticals to address a wide range of health conditions is surging.

Likewise, the livestock industry is witnessing a growing emphasis on disease prevention and productivity enhancement, fueling demand for specialized drugs. The rising prevalence of chronic diseases in animals, including arthritis, diabetes, and cardiovascular disorders, is pushing veterinary expenditures higher, prompting the development of more effective treatment options. Increasing awareness about preventive care, coupled with regulatory approvals for innovative veterinary pharmaceuticals, is further accelerating market growth. With ongoing R&D efforts and improved accessibility to veterinary care, the industry is poised for continued expansion.

Pharmaceutical innovations, in line with improved distribution networks, are making animal drugs more accessible across regions. Governments and private organizations are actively supporting veterinary research, leading to the introduction of advanced therapeutics designed to minimize recovery time and enhance overall animal well-being. Additionally, a surge in pet insurance coverage is encouraging pet owners to invest in high-quality medications, ensuring better treatment adherence.

The drugs segment led the market in 2024 with USD 23.8 billion, dominating due to its essential role in treating infections, inflammation, and parasitic infestations. Veterinary pharmaceuticals are increasingly being formulated to provide targeted treatment, reducing side effects and improving efficacy. The rising incidence of zoonotic diseases is also reinforcing the demand for advanced medications, prompting pharmaceutical companies to invest in cutting-edge research. Pet owners are becoming more proactive about their animals' health, opting for prescription medications that offer faster recovery and long-term benefits. Growing concerns over antimicrobial resistance are driving the adoption of alternative treatments, including probiotics and immunomodulators, further diversifying the drug landscape.

Companion animals accounted for 59.2% of the market share in 2024, reflecting the increasing number of households adopting pets and prioritizing their medical care. Rising disposable income, coupled with an emotional attachment to pets, is leading to higher veterinary spending, particularly on specialized medications. The demand for preventative treatments, including vaccines and nutritional supplements, is surging as pet owners seek to enhance their animals' longevity and quality of life. Technological advancements in veterinary diagnostics are also playing a key role in the segment's growth, enabling early disease detection and personalized treatment approaches.

North America accounted for 41.4% of the market share in 2024, maintaining its dominance due to high pet ownership rates and a well-established veterinary healthcare system. The region's significant livestock industry continues to drive demand for pharmaceuticals aimed at improving herd health and productivity. Expanding research initiatives, combined with growing regulatory support for innovative veterinary treatments, are reinforcing industry growth. The increasing availability of advanced treatment options, such as biologics and gene-based therapies, is shaping the future of animal healthcare, ensuring sustained demand for pharmaceuticals across the region.

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market scope and definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates and calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360⁰ synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising prevalence of animal diseases
    • 3.2.1.2 Growing focus on livestock productivity
    • 3.2.1.3 Surging demand for pet insurance policies
    • 3.2.1.4 Growing government initiatives and support towards animal welfare
    • 3.2.1.5 Intensified R&D activities drive advancements in veterinary medicine
    • 3.2.1.6 Expanding online veterinary pharmacies
  • 3.2.2 Industry pitfalls and challenges
    • 3.2.2.1 Adverse side effects and drug recalls
    • 3.2.2.2 High cost associated with animal drugs development
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
  • 3.4.1 North America
  • 3.4.2 Europe
  • 3.4.3 Asia Pacific
• 3.5 Policy landscape
• 3.6 Product pipeline analysis
• 3.7 Investor overview
• 3.8 GAP analysis
• 3.9 Consumer behaviour trends
• 3.10 Porter's analysis
• 3.11 PESTEL analysis

Chapter 4 Competitive Landscape, 2024

• 4.1 Introduction
• 4.2 Company matrix analysis
• 4.3 Company market share analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product, 2021 – 2034 ($ Mn)

• 5.1 Key trends
• 5.2 Drugs
  • 5.2.1 Antiparasitic
  • 5.2.2 Anti-inflammatory
  • 5.2.3 Anti-infectives
  • 5.2.4 Corticosteroids
  • 5.2.5 Tranquilizers
  • 5.2.6 Cardiovascular drugs
  • 5.2.7 Gastrointestinal drugs
• 5.3 Vaccines
  • 5.3.1 Modified live vaccines (MLV)
  • 5.3.2 Killed inactivated vaccines
  • 5.3.3 Recombinant vaccines
• 5.4 Medicated feed additives
  • 5.4.1 Antibiotics
  • 5.4.2 Vitamins
  • 5.4.3 Amino acids
  • 5.4.4 Enzymes
  • 5.4.5 Antioxidants
  • 5.4.6 Prebiotics and probiotics
  • 5.4.7 Minerals
  • 5.4.8 Other medicated feed additives

Chapter 6 Market Estimates and Forecast, By Animal Type, 2021 – 2034 ($ Mn)

• 6.1 Key trends
• 6.2 Companion animals
  • 6.2.1 Dogs
  • 6.2.2 Cats
  • 6.2.3 Horses
  • 6.2.4 Other companion animals
• 6.3 Livestock animals
  • 6.3.1 Poultry
  • 6.3.2 Swine
  • 6.3.3 Cattle
  • 6.3.4 Fish
  • 6.3.5 Other livestock animals

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 – 2034 ($ Mn)

• 7.1 Key trends
• 7.2 Oral
• 7.3 Injectable
• 7.4 Topical
• 7.5 Other routes of administration

Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2034 ($ Mn)

• 8.1 Key trends
• 8.2 Veterinary hospital pharmacies
• 8.3 E-commerce
• 8.4 Retail pharmacies

Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2034 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Poland
  • 9.3.7 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
  • 9.4.6 Taiwan
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 GCC Countries
  • 9.6.3 Israel

Chapter 10 Company Profiles

• 10.1 Agrolabo
• 10.2 Boehringer Ingelheim International
• 10.3 Ceva Santé Animale
• 10.4 Chanelle Pharma
• 10.5 Dechra Pharmaceuticals
• 10.6 Durvet
• 10.7 Elanco Animal Health
• 10.8 Endovac Animal Health
• 10.9 HIPRA
• 10.10 Indian Immunologicals
• 10.11 Merck
• 10.12 Norbrook
• 10.13 Neogen Corporation
• 10.14 Symrise
• 10.15 Vetoquinol
• 10.16 Virbac
• 10.17 Zoetis